C difficile risk
Oral Bioavailability


Requires AMS review within 72 hours. See below for more information.

  • Use total body weight in obesity

  • 6 mg/kg IV q24h (round to nearest 50mg)

  • Vial size is 500mg

  • 4 mg/kg IV q24h (round to nearest 50mg)

  • Vial size is 500mg

  • 8 - 10 mg/kg IV q24h (round to nearest 50mg)

  • Vial size is 500mg.

CrCl > 30 mL/minCrCl < 30 mL/minNo renal adjustment required 6 mg/kg IV q48h

6 mg/kg IV q48h

  • Give dose after dialysis on HD days

6 mg/kg IV q48h

6 - 8 mg/kg IV q48h

General Information

  • VRE

  • MRSA or other Gram-positive infections in patients who cannot receive 1st line agents

DO NOT use for pneumonia, inactivated by pulmonary surfactant

Creatine kinase weekly during prolonged therapy. Consider stopping statin while on therapy

  • Myopathy including rhabdomyolysis

  • Rare eosinophilic pneumonia

  • Statins and fibrates - Increased myopathy.

  • Monitor creatine kinase or hold while on daptomycin therapy.

  • Can obtain sensitivities on request

  • Higher doses used for endovascular infection.

  • Recommend Infectious Disease Consult.

  • Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.